Latest news with #AnandNambiar
National Post
15-07-2025
- Science
- National Post
MilliporeSigma Launches AAW™ Workstation to Advance Lab Automation
Article content New platform powered by Opentrons expands lab automation to accelerate scientific discovery Plug-and-play design for effortless integration into diverse laboratory settings Validated protocols across applications benefit academia, pharma, and biotech Article content BURLINGTON, Mass. — MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has launched the AAW™ Automated Assay Workstation, a solution powered by Opentrons, a leader in lab automation and accessible robotics. The workstation automates routine laboratory experiments previously performed manually, reducing hands-on time and ensuring consistency in results across diverse experimental settings. This launch follows the earlier announcement of a multi-year partnership with Opentrons Labworks, Inc. to enhance laboratory workflows through automation. Article content 'The AAW™ Workstation exemplifies our commitment to equipping scientists with solutions that simplify their workflows and enhance their research capabilities.' 'Our customers are increasingly seeking tools that improve efficiency and deliver reliable and reproducible results,' said Anand Nambiar, Head of Science & Lab Solutions, Life Science business of Merck KGaA, Darmstadt, Germany. 'The AAW™ exemplifies our commitment to equipping scientists with solutions that simplify their workflows and enhance their research capabilities. By automating routine tasks, researchers can focus on solving complex scientific challenges and accelerate discovery.' Article content Designed to advance the lab of the future, the AAW™ offers a plug-and-play setup and an extensive library of validated assay protocols across protein, molecular, and cell biology applications. Its versatility and ease of integration make it an ideal fit for academic, biotech, and pharmaceutical labs looking to boost productivity without compromising quality. Article content The AAW™ joins MilliporeSigma's growing portfolio of digital and automation innovations, including: Article content For more information about the AAW™ and to explore our full range of innovative solutions, visit Article content The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 26,000 employees and more than 55 total manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics. Article content Around 62,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck KGaA, Darmstadt, Germany, generated sales of € 21.2 billion in 65 countries. Article content The company holds the global rights to the name and trademark 'Merck' internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit Article content All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service. Article content About Opentrons Article content Opentrons Labworks, Inc., a disruptive life science company and the current market leader in entry-level lab automation, accelerates innovation in research and healthcare through its integrated lab platform, which includes business units Opentrons ® Robotics and Neochromosome™. Opentrons has raised over $200 million in funding and achieved unicorn status based on its innovative technologies. The Opentrons Flex ® is Opentrons' newest generation of liquid-handling lab robots, offering open-source accessibility and compatibility with generative AI tools. Opentrons Robotics provides thousands of institutions with flexible, easy-to-use lab robots, automating R&D operations and making robotics, a vast open-source library accessible to life sciences researchers worldwide. Opentrons is used in labs at the top 20 academic universities in the US and 14 of 15 leading global biopharmaceutical companies. Learn more at Article content Article content Article content Contacts Article content Article content
Yahoo
15-07-2025
- Business
- Yahoo
MilliporeSigma Launches AAW™ Workstation to Advance Lab Automation
New platform powered by Opentrons expands lab automation to accelerate scientific discovery Plug-and-play design for effortless integration into diverse laboratory settings Validated protocols across applications benefit academia, pharma, and biotech BURLINGTON, Mass., July 15, 2025--(BUSINESS WIRE)--MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has launched the AAW™ Automated Assay Workstation, a solution powered by Opentrons, a leader in lab automation and accessible robotics. The workstation automates routine laboratory experiments previously performed manually, reducing hands-on time and ensuring consistency in results across diverse experimental settings. This launch follows the earlier announcement of a multi-year partnership with Opentrons Labworks, Inc. to enhance laboratory workflows through automation. "Our customers are increasingly seeking tools that improve efficiency and deliver reliable and reproducible results," said Anand Nambiar, Head of Science & Lab Solutions, Life Science business of Merck KGaA, Darmstadt, Germany. "The AAW™ exemplifies our commitment to equipping scientists with solutions that simplify their workflows and enhance their research capabilities. By automating routine tasks, researchers can focus on solving complex scientific challenges and accelerate discovery." Designed to advance the lab of the future, the AAW™ offers a plug-and-play setup and an extensive library of validated assay protocols across protein, molecular, and cell biology applications. Its versatility and ease of integration make it an ideal fit for academic, biotech, and pharmaceutical labs looking to boost productivity without compromising quality. The AAW™ joins MilliporeSigma's growing portfolio of digital and automation innovations, including: M-Trace® Software: The first software offering complete data traceability in microbial QC. MyMilli-Q™ Services: A digital platform for water purification system oversight, ensuring high-quality water for critical experiments. ChemisTwin® Platform: The first-ever digital reference material platform that confirms compound structures and quantifies samples. For more information about the AAW™ and to explore our full range of innovative solutions, visit About the Life Science business of Merck KGaA, Darmstadt, Germany The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 26,000 employees and more than 55 total manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics. Around 62,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck KGaA, Darmstadt, Germany, generated sales of € 21.2 billion in 65 countries. The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn. All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service. About Opentrons Opentrons Labworks, Inc., a disruptive life science company and the current market leader in entry-level lab automation, accelerates innovation in research and healthcare through its integrated lab platform, which includes business units Opentrons® Robotics and Neochromosome™. Opentrons has raised over $200 million in funding and achieved unicorn status based on its innovative technologies. The Opentrons Flex® is Opentrons' newest generation of liquid-handling lab robots, offering open-source accessibility and compatibility with generative AI tools. Opentrons Robotics provides thousands of institutions with flexible, easy-to-use lab robots, automating R&D operations and making robotics, a vast open-source library accessible to life sciences researchers worldwide. Opentrons is used in labs at the top 20 academic universities in the US and 14 of 15 leading global biopharmaceutical companies. Learn more at View source version on Contacts Media Relations Phone: +1.314.296.8288 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Korea Herald
20-02-2025
- Business
- Korea Herald
Merck showcases AI chip materials platform at Semicon Korea 2025
German technology firm Merck showcased its new artificial intelligence-driven chip materials platform, which has impressively reduced research and development time for critical materials used in advanced chips, at this year's Semicon Korea, Thursday. 'Without materials, AI wouldn't be possible. To power AI, we need powerful, compact and energy efficient chips, which increases complexity in both chip architecture and manufacturing processes," said Anand Nambiar, chief commercial officer of Merck Electronics, during a press conference held on the sidelines of Semicon Korea 2025, running from Wednesday to Friday in Seoul. "This is where materials solutions can play a critical role in addressing the physical and economic challenges faced by chipmakers." According to Nambiar, Merck's Materials Intelligence platform has enabled the company's researchers to run simulations instead of physical experiments to effectively reduce the time needed for its basic chemistry research. "We're learning how data digitalization is helping us answer some of the challenges that we've faced for decades," the CCO said. As demand is rising for advanced AI chips, Merck is working to converge material science with AI to develop new solutions for AI-enabling technologies, including Gate All-Around, high-density memory and HBM chips. This year, the company will also focus on facility investment, especially on thin-film materials and specialty gases. Regarding the impact of the second-term of the Trump administration, Nambiar acknowledged there may be "a little transition" as governments, including the US and Japan, are introducing measures to bring chip manufacturing onto their soil. "Asia still represents 80 percent of semiconductor capacity. Korea and Taiwan are leading countries where capacity is installed, and leading edge customers are present," Nambiar said. During the three-day Semicon event, Merck focused on materials for advanced logic and 3D densification in DRAM and 3D NAND memory chips. This includes enhanced features in Atomic Layer Deposition for advanced nodes, spin-on dielectrics (SOD) materials for gap fill technology and organometallics solutions for FinFet-architecture DRAM, among others. "We have been an innovation partner to our Korean customers for 36 years, and we are committed to supporting their future growth. This includes the recently inaugurated Korea SOD Application Center in Anseong, announced last year, and ongoing investments in new product lines at the Eumseong site," said Kim Woo-kyu, managing director of Merck Korea. "We will continue to fulfill our investment commitment to enhance our local capability and capacity for faster and more responsive support and services." The Germany-based chemical materials firm entered the Korean market in 1989, and now operates 13 production and R&D sites with over 1,700 employees, making Korea its second-largest business hub after the US.
